Huaren Pharmaceutical Past Earnings Performance
Past criteria checks 2/6
Huaren Pharmaceutical has been growing earnings at an average annual rate of 24.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 2.3% per year. Huaren Pharmaceutical's return on equity is 5.4%, and it has net margins of 9.8%.
Key information
24.1%
Earnings growth rate
24.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 2.3% |
| Return on equity | 5.4% |
| Net Margin | 9.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Huaren Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 1,494 | 147 | 156 | 75 |
| 30 Jun 24 | 1,579 | 179 | 213 | 75 |
| 31 Mar 24 | 1,640 | 198 | 250 | 72 |
| 31 Dec 23 | 1,636 | 188 | 262 | 69 |
| 30 Sep 23 | 1,731 | 195 | 382 | 59 |
| 30 Jun 23 | 1,727 | 189 | 378 | 59 |
| 31 Mar 23 | 1,637 | 197 | 329 | 59 |
| 01 Jan 23 | 1,619 | 181 | 369 | 55 |
| 30 Sep 22 | 391 | 136 | 415 | 54 |
| 30 Jun 22 | 1,580 | 131 | 427 | 54 |
| 31 Mar 22 | 1,603 | 131 | 457 | 58 |
| 01 Jan 22 | 1,561 | 130 | 442 | 64 |
| 30 Sep 21 | 2,578 | 158 | 325 | 66 |
| 30 Jun 21 | 1,433 | 133 | 345 | 63 |
| 31 Mar 21 | 1,419 | 114 | 363 | 61 |
| 31 Dec 20 | 1,317 | 95 | 358 | 55 |
| 30 Sep 20 | 1,383 | 71 | 448 | 59 |
| 30 Jun 20 | 1,337 | 64 | 498 | 60 |
| 31 Mar 20 | 1,370 | 43 | 589 | 57 |
| 31 Dec 19 | 1,462 | 42 | 634 | 62 |
| 30 Sep 19 | 1,468 | 36 | 680 | 61 |
| 30 Jun 19 | 1,445 | 35 | 677 | 60 |
| 31 Mar 19 | 1,394 | 41 | 647 | 57 |
| 31 Dec 18 | 1,384 | 39 | 637 | 56 |
| 30 Sep 18 | 1,404 | 42 | 622 | 53 |
| 30 Jun 18 | 1,376 | 45 | 551 | 74 |
| 31 Mar 18 | 1,364 | 36 | 529 | 65 |
| 01 Jan 18 | 1,312 | 38 | 504 | 49 |
| 30 Sep 17 | 1,254 | 33 | 472 | 32 |
| 30 Jun 17 | 1,253 | 29 | 493 | 0 |
| 31 Mar 17 | 1,244 | 26 | 466 | 0 |
| 31 Dec 16 | 1,249 | 24 | 439 | 0 |
| 30 Sep 16 | 1,209 | 6 | 435 | 0 |
| 30 Jun 16 | 1,187 | 5 | 391 | 0 |
| 31 Mar 16 | 1,140 | 10 | 392 | 0 |
| 31 Dec 15 | 1,106 | 23 | 382 | 0 |
| 30 Sep 15 | 1,013 | 29 | 354 | 0 |
| 30 Jun 15 | 1,010 | 45 | 353 | 0 |
| 31 Mar 15 | 961 | 42 | 335 | 0 |
| 31 Dec 14 | 917 | 56 | 318 | 0 |
| 30 Sep 14 | 1,004 | 96 | 313 | 0 |
| 30 Jun 14 | 912 | 105 | 304 | 0 |
| 31 Mar 14 | 905 | 125 | 286 | 0 |
| 31 Dec 13 | 867 | 122 | 277 | 0 |
Quality Earnings: 300110 has high quality earnings.
Growing Profit Margin: 300110's current net profit margins (9.8%) are lower than last year (11.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300110's earnings have grown significantly by 24.1% per year over the past 5 years.
Accelerating Growth: 300110's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300110 had negative earnings growth (-24.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).
Return on Equity
High ROE: 300110's Return on Equity (5.4%) is considered low.